Palvella Therapeutics (PVLA) Non-Current Deffered Revenue (2016 - 2023)

Palvella Therapeutics (PVLA) has reported Non-Current Deffered Revenue for 8 consecutive years, with $759000.0 the latest figure, recorded in Q2 2023.

• In Q2 2023, Non-Current Deffered Revenue changed N/A year-over-year to $759000.0; the TTM figure through Jun 2023 stood at $759000.0 (changed N/A YoY), while the FY2022 annual figure was $18.7 million, down 51.22% from the prior year.
• Non-Current Deffered Revenue slipped to $759000.0 in Q2 2023 per PVLA's latest filing, from $11.7 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $59.7 million in Q1 2019 and bottomed at $759000.0 in Q2 2023.
• Historically, Non-Current Deffered Revenue has averaged $35.6 million across 5 years, with a median of $37.8 million in 2020.
• Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue soared 30.59% — and 2023, when it slumped 61.95%.
• Palvella Therapeutics' Non-Current Deffered Revenue stood at $47.3 million in 2019, then retreated by 24.03% to $35.9 million in 2020, then grew by 6.97% to $38.4 million in 2021, then sank by 51.22% to $18.7 million in 2022, then tumbled by 95.95% to $759000.0 in 2023.
• Business Quant data shows PVLA's Non-Current Deffered Revenue at $759000.0 in Q2 2023, $11.7 million in Q1 2023, and $18.7 million in Q4 2022.